Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial

BACKGROUND: Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism (VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis. This has been evidenced in preclinical models, with an inhibitory effect of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Castle, John, Blower, Emma, Bundred, Nigel J., Harvey, James R., Thachil, Jecko, Marshall, Andrea, Cox, Karina, Cicconi, Silvia, Holcombe, Chris, Palmieri, Carlos, Kirwan, Cliona C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534806/
https://www.ncbi.nlm.nih.gov/pubmed/32854772
http://dx.doi.org/10.1186/s13063-020-04675-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534806/
https://www.ncbi.nlm.nih.gov/pubmed/32854772
http://dx.doi.org/10.1186/s13063-020-04675-7

Ejemplares similares